Tucaliv 50 Mg Tablets

Composition:

Tucatinib 50mg

About Tucaliv 50 Mg Tablets

Tucatinib is indicated for the treatment of

1. In combination of trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2 positive metastatic breast cancer, including those patients with brain metastases who have received one or more prior anti - HER2 therapies in metastatic setting.
2. Indicated in combination with trastuzumab for treatment of adult patients with RAS wild type, HER2 positive, unresectable, metastatic colorectal cancer that ahs progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan-based therapy.

Tucatinib is available as 50 mg tablets. Your doctor will prescribe the tablets at a dose of 300 mg to be taken twice daily with or without food. It may also be possible that you are prescribed a lower dose of the drug based on your disease profile.

You should inform your doctor regarding any specific allergies you have or if you are on any other medications. Please do inform your doctor if you are pregnant or lactating.

The most common adverse reactions (≥20%) with tucatinib in combination with trastuzumab and capecitabine in patients with metastatic breast cancer are diarrhea, palmar-plantar erythrodysesthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash.

The most common adverse reactions (≥20%) with tucatinib in combination with trastuzumab in patients with unresectable or metastatic colorectal cancer are diarrhea, fatigue, rash, nausea, abdominal pain, infusion related reactions, and pyrexia.